EUVIMEDEUVIMED entdecken
Crossref

Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody

Isabell Singerer, Laura Tempel, Katja Gruen, Judith Heiß, Clara Gutte, Mattia Matasci, Andrea Schrepper, Reinhard Bauer, Alexander Berndt, Christian Jung, P Christian Schulze, Dario Neri und 1 weitere

Cardiovascular Research · 2024

DOI: 10.1093/cvr/cvae146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Isabell Singerer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Fibronectins, Mice, Knockout, Disease Models, Animal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pulmonary vascular and right ventricular (RV) remodelling processes are important for development and progression of pulmonary hypertension (PH). The current study analysed the functional role of the extra domain A-containing fibronectin (ED-A+ Fn) for the development of PH by comparing ED-A+ Fn knockout (KO) and wild-type (WT) mice as well as the effects of an antibody-based therapeutic approach in a model of monocrotaline (MCT)-induced PH, which will be validated in a model of Sugen 5416/hypoxia-induced PH. Methods and results PH was induced using MCT (PH mice). Sixty-nine mice were divided into the following groups: sham-treated controls (WT: n = 7; KO: n = 7), PH mice without specific treatment (WT: n = 12; KO: n = 10), PH mice treated with a dual endothelin receptor antagonist (macitentan; WT: n = 6; KO: n = 11), WT PH mice treated with the F8 antibody, specifically recognizing ED-A+ Fn, (n = 8), and WT PH mice treated with an antibody of irrelevant antigen specificity (KSF, n = 8). Compared to controls, WT_PH mice showed a significant elevation of the RV systolic pressure (P = 0.04) and RV functional impairment including increased basal RV (P = 0.016) diameter or tricuspid annular plane systolic excursion (P = 0.008). In contrast, KO PH did not show such effects compared to controls (P = n.s.). In WT_PH mice treated with F8, haemodynamic and echocardiographic parameters were significantly improved compared to untreated WT_PH mice or those treated with the KSF antibody (P < 0.05). On the microscopic level, KO_PH mice showed significantly less tissue damage compared to the WT_PH mice (P = 0.008). Furthermore, lung tissue damage could significantly be reduced after F8 treatment (P = 0.04). Additionally, these findings could be verified in the Sugen 5416/hypoxia mouse model, in which F8 significantly improved echocardiographic, haemodynamic, and histologic parameters.

Conclusion

ED-A+ Fn is of crucial importance for PH pathogenesis representing a promising therapeutic target in PH. We here show a novel therapeutic approach using antibody-mediated functional blockade of ED-A+ Fn capable of attenuating and partially reversing PH-associated tissue remodelling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryFibronectinsMice, KnockoutDisease Models, AnimalMonocrotalineVentricular Function, RightVentricular RemodelingMice, Inbred C57BLAnimalsPyrimidinesPulmonary ArteryMaleEndothelin Receptor AntagonistsVascular RemodelingAntibodies, BlockingAntibodies, MonoclonalHypertrophy, Right VentricularSulfonamides

Stichwörter der Autor:innen

Antibody therapyDisease modificationPulmonary hypertensionRemodelling

Substanzen

FibronectinsMonocrotalineextra domain A fibronectin, mousemacitentanPyrimidinesEndothelin Receptor AntagonistsAntibodies, BlockingAntibodies, MonoclonalSulfonamides

Autor:innen und Institutionen

  • Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.
  • Department of Cardiology, Angiology and Intensive Care Medicine, Cardiovascular Center Rotenburg, Klinikum Hersfeld-Rotenburg, Heinz-Meise-Str. 100, 36199 Rotenburg an der Fulda, Germany.
  • Philochem AG, Otelfingen, Switzerland.
  • Department of Cardiothoracic Surgery, University Hospital Jena, Jena, Germany.
  • Center for Molecular Biomedicine, Institute of Molecular Cell Biology, University Hospital Jena, Jena, Germany.
  • Section Pathology, Institute of Legal Medicine, University Hospital Jena, Jena, Germany.

Zitieren

APA

Singerer, I., Tempel, L., Gruen, K., Heiß, J., Gutte, C., Matasci, M., Schrepper, A., Bauer, R., Berndt, A., Jung, C., Schulze, P. C., Neri, D., & Franz, M. (2024). Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae146

Vancouver

Singerer I, Tempel L, Gruen K, Heiß J, Gutte C, Matasci M, et al. Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae146

BibTeX
@article{Singerer2024,
  author = {Singerer, Isabell and Tempel, Laura and Gruen, Katja and Heiß, Judith and Gutte, Clara and Matasci, Mattia and Schrepper, Andrea and Bauer, Reinhard and Berndt, Alexander and Jung, Christian and Schulze, P Christian and Neri, Dario and Franz, Marcus},
  title = {Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody},
  journal = {Cardiovascular Research},
  year = {2024},
  doi = {10.1093/cvr/cvae146}
}
Kostenlos starten →